What is the next systemic therapy for a patient with advanced disease refractory to lenvatinib (Lenvima)?

Treatment After Lenvatinib (Lenvima) Failure

For hepatocellular carcinoma (HCC) patients who progress on lenvatinib, the preferred second-line options are cabozantinib, regorafenib (if lenvatinib was tolerated), or ramucirumab (if AFP ≥400 ng/mL), with atezolizumab plus bevacizumab as an alternative if not previously used. 1

Disease-Specific Recommendations

Hepatocellular Carcinoma (HCC)

The ASCO 2024 guidelines explicitly address post-lenvatinib therapy, acknowledging that while second-line data primarily comes from post-sorafenib studies, these can be cautiously extrapolated to lenvatinib-refractory patients since both are TKIs 1.

Second-line options include:

• Cabozantinib: Evaluated in patients refractory or intolerant to prior systemic therapy, making it broadly applicable after lenvatinib failure 1

• Regorafenib: FDA-approved post-sorafenib, but requires that patients tolerated at least 400 mg of sorafenib for ≥20 days in the prior 28-day period. Given its nearly identical molecular structure to sorafenib and similar toxicity profile, use cautiously after lenvatinib 1

• Ramucirumab: Specifically for patients with AFP ≥400 ng/mL who are refractory/intolerant to prior therapy 1

• Atezolizumab plus bevacizumab: May be considered as second-line in select patients who progressed on lenvatinib and have no contraindications to this combination 1

Critical selection factors:

• Child-Pugh A liver function required
• ECOG performance status 0-1
• Absence of contraindications (particularly for bevacizumab: bleeding risk, recent GI perforation)
• AFP level (if ≥400 ng/mL, ramucirumab becomes an option)

Recent real-world data from 2026 suggests lenvatinib continuation beyond progression may offer modest disease control (50% disease control rate, median second PFS 6.0 months) in carefully selected patients where subsequent-line therapies are unavailable 2, though this is not a guideline-endorsed approach.

Differentiated Thyroid Cancer (DTC)

For radioiodine-refractory DTC progressing on lenvatinib, the approach differs significantly:

Primary strategy:

• Cabozantinib: Best-supported option after lenvatinib failure 3
• Molecular testing: Essential to identify actionable alterations (RET, NTRK, ALK fusions) that warrant selective targeted inhibitors 3

Alternative approaches:

• Lenvatinib plus pembrolizumab: A 2024 study showed 16% confirmed response rate and median PFS of 10.0 months in lenvatinib-refractory patients, offering a viable salvage option 4
• Lenvatinib rechallenge: After intervening sorafenib, rechallenge achieved median PFS of 15.0 months in a 2024 real-world study, providing an alternative when selective inhibitors aren't indicated 5

Key considerations:

• Early molecular testing is critical—selective RET, NTRK, and ALK inhibitors have reshaped treatment for fusion-positive disease 3
• MAPK inhibition can restore radioiodine avidity in selected tumors 3
• Immunotherapy combinations show promise but remain investigational

Renal Cell Carcinoma (RCC)

The FDA label indicates lenvatinib is used first-line with pembrolizumab or second-line with everolimus after prior anti-angiogenic therapy 6. Post-lenvatinib sequencing would follow standard RCC treatment algorithms with alternative TKIs or immunotherapy combinations.

Endometrial Carcinoma (EC)

Lenvatinib is used with pembrolizumab for pMMR/not MSI-H advanced EC after prior systemic therapy 6. Post-progression options would follow standard EC treatment pathways.

Common Pitfalls to Avoid

1. Don't assume sorafenib data directly applies to lenvatinib: While ASCO states cautious extrapolation is reasonable, molecular structures and toxicity profiles differ 1

2. Don't use regorafenib without confirming prior TKI tolerance: Regorafenib requires documented tolerance of adequate doses 1

3. Don't overlook AFP levels in HCC: AFP ≥400 ng/mL specifically qualifies patients for ramucirumab 1

4. Don't skip molecular testing in thyroid cancer: Actionable fusions may warrant selective inhibitors over sequential TKIs 3

5. Don't continue lenvatinib beyond progression without careful patient selection: While some data supports this in resource-limited settings, it's not standard practice and requires baseline progressive disease assessment 7

Treatment Selection Algorithm

For HCC patients (Child-Pugh A, ECOG 0-1):

1. Check AFP level
   • If AFP ≥400 ng/mL → Consider ramucirumab
   • If AFP <400 ng/mL → Proceed to step 2
2. Assess lenvatinib tolerance
   • If well-tolerated → Cabozantinib or regorafenib
   • If poorly tolerated → Cabozantinib preferred
3. Consider atezolizumab/bevacizumab if not used first-line and no contraindications exist

For DTC patients:

1. Obtain molecular testing immediately
   • If RET/NTRK/ALK fusion → Selective inhibitor
   • If no actionable alteration → Proceed to step 2
2. Consider cabozantinib as standard second-line
3. Evaluate for lenvatinib/pembrolizumab combination or clinical trial enrollment